Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.

@article{Dillon2016TrastuzumabdeBouganinCO,
  title={Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.},
  author={R. L. Dillon and Shilpa Chooniedass and Arjune Premsukh and Gregory P. Adams and Joycelyn Entwistle and Glen C Macdonald and Jeannick Cizeau},
  journal={Journal of immunotherapy},
  year={2016},
  volume={39 3},
  pages={117-26}
}
The development of antibody drug conjugates has provided enhanced potency to tumor-targeting antibodies by the addition of highly potent payloads. In the case of trastuzumab-DM1 (T-DM1), approved for the treatment of metastatic breast cancer, the addition of mertansine (DM1) to trastuzumab substantially increased progression-free survival. Despite these improvements, most patients eventually relapse due to complex mechanisms of resistance often associated with small molecule chemotherapeutics… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…